This content is from: Research
Asia (ex-Japan’s) Top Corporate Access Providers
Some content in this section is locked. To get access to all of the research, please subscribe here or login.
Methodology
To select the members for Institutional Investor’s 2022 Asia’s Top Corporate Access Providers, we invited participants in the 2022 Asia Research Team and 2022 Asia Executive Team Surveys to provide feedback on the firms that provided the best corporate access on a number of attributes.
From the 2022 Asia Research Team survey, representing the buy-side point of view, we received responses from 717 investors at 422 firms. This group rated sell-side firms on a scale from 1 to 5 across the following corporate access attributes: Team Quality, Field Trips, Conferences, Roadshows, Logistics, and Virtual Events.
Each vote was weighted by the voting firm’s Asia (ex-Japan) commission range and the rating awarded to create the rankings. Additionally, a second result was created using the assets under management, rather than commissions, as the weighting.
The Corporate Access Leaders table, based on the buy-side voter’s survey, was calculated by adding together a firm’s overall corporate access scores within each attribute to produce a table of the top-ten firms.
From the 2022 Asia Executive Team Survey, representing the corporate point of view, 227 corporates voted for both sell-side firms and third-party providers. Voters ranked their top four firms in the following attributes: Virtual conferences, Feedback, Investor introductions or ad hoc requests, Nondeal road shows, and Site visits. Each attribute score was based on the place awarded to the firm. Scores were then aggregated to create the overall result.
The Corporate Access Leaders table, based on the corporates’ responses, tabulated each firm’s overall scores to produce a table comprised of the top-ten firms.
The names of those surveyed are kept confidential to ensure their continuing cooperation. Voters are required to meet eligibility requirements, and all ballots are subject to review by II’s Research Operations Group.